Background
==========

Varenicline is currently the most effective smoking cessation medication. Pre-marketing clinical trials excluded participants with psychiatric disorders, such as major depressive disorders. This study investigated the psychiatric effects of varenicline among patients with depression.

Methods
=======

On 18 December 2012, a systematic search was performed using Medline with the following search terms: 1) varenicline and 2) depression. The search was limited to English articles, case reports, and original clinical studies. From the 58 retrieved documents, 15 articles were used in this review.

Results
=======

The first case report on the effects of varenicline on patients with depression was published in June 2008. A man experienced an acute exacerbation of depressive symptoms, which resolved after he stopped his varenicline treatment. \[[@B1]\] Since then, there were 8 other case reports that described exacerbation of psychiatric symptoms in patients with depression taking varenicline \[[@B2]-[@B9]\]. Two of those case studies suggested the use of sertraline \[[@B7]\] and bupropion \[[@B8]\] to treat exacerbation of depressive symptoms associated with varenicline. In contrast, varenicline was shown to improve the affective symptoms of a smoker who developed depression and suicidal tendencies during previous cessation attempts \[[@B10]\]. There were 3 observational studies on patients with depression taking varenicline: 1) a one-year follow-up study on 112 smokers showed an association between increased Beck Depression Inventory score and continued smoking after 12 weeks of varenicline \[[@B11]\]; 2) an open-labelled study showed significant improvement in mood in 110 outpatient smokers with persistent depressive symptoms \[[@B12]\]; and 3) A smoking cessation trial on 217 varenicline users showed that depressive symptoms at the time of varenicline initiation (measured by Patient Health Questionnaire-2) were associated with suicidal ideation. \[[@B13]\] There were 2 clinical trials on patients with depression taking varenicline, with both of them showing worsening of psychiatric symptoms. \[[@B14],[@B15]\] Neither of the trials were placebo-controlled.

Conclusions
===========

Despite some inconsistencies, the findings suggested that varenicline could worsen psychiatric symptoms in patients with depression. Clinicians should be advised to closely monitor patients with a history of depression on varenicline, although there were no studies on how to treat those patients. Bias and uncontrolled confounders potentially affected previous studies, and thus, a double-blinded placebo-controlled trial is needed to demonstrate the efficacy and side effects of varenicline on patients with depression.
